Oral methylphenidate establishes a conditioned place preference in rats.

  • Professor and Director - Center for Drug Abuse Research Translation
  • BNP
  • Psychology
BBSRB, Room 447
859.257.6456
TitleOral methylphenidate establishes a conditioned place preference in rats.
Publication TypeJournal Article
Year of Publication2011
JournalNeuroscience letters
Volume487
Issue3
Pagination293-6
Date Published2011
ISSN0304-3940
Abstract

Emerging data suggest that illicit methylphenidate abuse is a growing problem. Although abuse of the drug typically occurs by the intranasal route, oral (per os; p.o.) methylphenidate also has abuse potential. The present study compared the effects of p.o. and intraperitoneal (i.p.) methylphenidate in rats using the conditioned place preference (CPP) procedure. Young adult male Sprague-Dawley rats were trained to consume oyster crackers injected initially with saline. Next, rats were randomly assigned to receive p.o. or i.p. methylphenidate (3 or 10mg/kg) or saline immediately or 30min prior to 30min conditioning trials. Methylphenidate or saline were each paired 4 times with an end compartment; preference for the methylphenidate-paired compartment was then assessed on a drug-free session. When given immediately prior to conditioning, significant CPP was obtained with both 3 and 10mg/kg of i.p. methylphenidate, but only with 10mg/kg of p.o. methylphenidate. When given 30min prior to conditioning, there was no evidence of CPP for any dose of i.p. or p.o. methylphenidate. These findings are the first demonstration that p.o. methylphenidate has rewarding effects, although i.p. methylphenidate is obtained at a 3mg/kg dose which did not establish CPP with p.o. administration. The lack of CPP following 30min pretreatment also suggests that conditioning may require the CS to be associated with a US of ascending, rather than descending, brain levels of methylphenidate. These results are consistent with clinical evidence of the reduced abuse liability of p.o. methylphenidate relative to methylphenidate taken by other (e.g., intranasal) routes.

URLhttps://linkinghub.elsevier.com/retrieve/pii/S0304-3940(10)01393-5
DOI10.1016/j.neulet.2010.10.040
Short TitleNeurosci Lett
X
Enter your linkblue username.
Enter your linkblue password.
Secure Login

This login is SSL protected

Loading